Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biocryst Pharma Inc (BCRX)

Biocryst Pharma Inc (BCRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 276,095
  • Shares Outstanding, K 110,438
  • Annual Sales, $ 20,650 K
  • Annual Income, $ -101,250 K
  • 60-Month Beta 1.95
  • Price/Sales 13.31
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.31
  • Number of Estimates 5
  • High Estimate -0.27
  • Low Estimate -0.35
  • Prior Year -0.28
  • Growth Rate Est. (year over year) -10.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.35 +1.49%
on 10/10/19
3.33 -28.38%
on 09/27/19
-0.43 (-15.43%)
since 09/18/19
3-Month
2.35 +1.49%
on 10/10/19
3.52 -32.24%
on 07/19/19
-1.10 (-31.47%)
since 07/18/19
52-Week
2.35 +1.49%
on 10/10/19
9.95 -76.03%
on 01/28/19
-4.81 (-66.83%)
since 10/18/18

Most Recent Stories

More News
Watch for Biocryst Pharm to Potentially Rebound After Falling 2.20% Yesterday

Biocryst Pharm (NASDAQ:BCRX) traded in a range yesterday that spanned from a low of $2.41 to a high of $2.53. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $2.45...

BCRX : 2.38 (-4.60%)
BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted three newly-hired employees options to purchase an aggregate of 103,000...

BCRX : 2.38 (-4.60%)
U.S. Government Exercises Option for Additonal Rapivab(R) for Strategic National Stockpile

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCryst's approved...

BCRX : 2.38 (-4.60%)
BioCryst Pharmaceuticals to Present at Cantor Global Healthcare Conference

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present at the Cantor Global Healthcare Conference in New York on Friday, October 4, 2019 at 12:35 p.m. ET.

BCRX : 2.38 (-4.60%)
BioCryst Appoints Helen Thackray, M.D., to Board of Directors

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed clinical rare disease expert, Helen Thackray, M.D., FAAP, to its board of directors.

BCRX : 2.38 (-4.60%)
BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted five newly-hired employees options to purchase an aggregate of 112,500...

BCRX : 2.38 (-4.60%)
BioCryst to Present at H.C. Wainwright Global Investment Conference

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the H.C. Wainwright Global Investment Conference in New York on Monday, September 9, 2019 at 9:10 a.m. ET.

BCRX : 2.38 (-4.60%)
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Lags Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of -9.68% and -42.43%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

BCRX : 2.38 (-4.60%)
BioCryst Reports Second Quarter 2019 Financial Results

--New drug application for once-daily oral BCX7353 for prophylaxis of hereditary angioedema attacks

BCRX : 2.38 (-4.60%)
BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted six newly-hired employees options to purchase an aggregate of 42,000...

BCRX : 2.38 (-4.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Good. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade BCRX with:

Business Summary

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential...

See More

Key Turning Points

2nd Resistance Point 2.61
1st Resistance Point 2.50
Last Price 2.38
1st Support Level 2.33
2nd Support Level 2.27

See More

52-Week High 9.95
Fibonacci 61.8% 7.05
Fibonacci 50% 6.15
Fibonacci 38.2% 5.25
Last Price 2.38
52-Week Low 2.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar